Image may be NSFW.
Clik here to view.-logo.jpg "Veru logo"){kind=logo}
Veru (NASDAQ:VERU)‘s stock had its “buy” rating reaffirmed by investment analysts at Brookline Capital Management in a report released on Friday, Zacks.com reports.
A number of other equities analysts have also commented on VERU. Oppenheimer reissued a “buy” rating and issued a $9.00 price objective on shares of Veru in a research note on Friday. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Veru in a research report on Monday, June 22nd. ValuEngine downgraded Veru from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Zacks Investment Research upgraded Veru from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Veru has a consensus rating of “Buy” and a consensus target price of $6.33.
Shares of NASDAQ VERU opened at $2.75 on Friday. Veru has a 12 month low of $1.67 and a 12 month high of $4.74. The company has a market cap of $206.75 million, a P/E ratio of -18.33 and a beta of 0.33. The business’s 50 day moving average is $3.09 and its two-hundred day moving average is $3.44. The company has a quick ratio of 0.68, a current ratio of 1.04 and a debt-to-equity ratio of 0.07.
Veru (NASDAQ:VERU) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.02). Veru had a negative net margin of 25.53% and a negative return on equity of 31.14%. Sell-side analysts expect that Veru will post -0.14 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Holdings Inc. increased its holdings in Veru by 199.1% in the second quarter. Advisor Group Holdings Inc. now owns 10,515 shares of the company’s stock valued at $35,000 after purchasing an additional 7,000 shares during the last quarter. American International Group Inc. bought a new stake in Veru in the second quarter valued at about $101,000. Bank of New York Mellon Corp increased its holdings in Veru by 489.7% in the second quarter. Bank of New York Mellon Corp now owns 132,695 shares of the company’s stock valued at $443,000 after purchasing an additional 110,194 shares during the last quarter. California Public Employees Retirement System increased its holdings in Veru by 14.5% in the second quarter. California Public Employees Retirement System now owns 109,788 shares of the company’s stock valued at $367,000 after purchasing an additional 13,888 shares during the last quarter. Finally, HighTower Advisors LLC bought a new stake in Veru in the second quarter valued at about $62,000. Institutional investors and hedge funds own 16.33% of the company’s stock.
About Veru
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
